IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment

Bade BC, Dela Cruz CS (2020) Lung Cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med 41:1–24

Schabath MB, Cote ML (2019) Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev 28:1563–1579

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249

Komohara Y, Fujiwara Y, Ohnishi K, Takeya M (2016) Tumor-associated macrophages: potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev 99:180–185

Pittet MJ, Michielin O, Migliorini D (2022) Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol 19:402–421

Matsubara E, Yano H, Pan C, Komohara Y, Fujiwara Y, Zhao S, Shinchi Y, Kurotaki D, Suzuki M (2023) The significance of SPP1 in lung cancers and its impact as a marker for protumor tumor-associated macrophages. Cancers (Basel) 15:2250

Shinchi Y, Ishizuka S, Komohara Y, Matsubara E, Mito R, Pan C, Yoshii D, Yonemitsu K, Fujiwara Y, Ikeda K, Tamada K, Sakagami T, Suzuki M (2022) The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol Immunother 71:2645–2661

Matsubara E, Shinchi Y, Komohara Y, Yano H, Pan C, Fujiwara Y, Ikeda K, Suzuki M (2023) PD-L2 overexpression on tumor-associated macrophages is one of the predictors for better prognosis in lung adenocarcinoma. Med Mol Morphol 56:250–256

Osman A, Bhuyan F, Hashimoto M, Nasser H, Maekawa T, Suzu S (2014) M-CSF inhibits anti-HIV-1 activity of IL-32, but they enhance M2-like phenotypes of macrophages. J Immunol 192:5083–5089

Nasser H, Takahashi N, Eltalkhawy YM, Reda O, Lotfi S, Nasu K, Sakuragi JI, Suzu S (2022) Inhibitory and stimulatory effects of IL-32 on HIV-1 Infection. J Immunol 209:970–978

Shinchi Y, Komohara Y, Yonemitsu K, Sato K, Ohnishi K, Saito Y, Fujiwara Y, Mori T, Shiraishi K, Ikeda K, Suzuki M (2019) Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: a retrospective study by double immunohistochemistry. Cancer Sci 110:2711–2721

Nakagawa T, Ohnishi K, Kosaki Y, Saito Y, Horlad H, Fujiwara Y, Takeya M, Komohara Y (2017) Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop 57:31–36

Saito Y, Fujiwara Y, Shinchi Y, Mito R, Miura Y, Yamaguchi T, Ikeda K, Urakami S, Nakashima Y, Sakagami T, Suzuki M, Tabata Y, Komohara Y (2022) Classification of PD-L1 expression in various cancers and macrophages based on immunohistocytological analysis. Cancer Sci 113:3255–3266

Horlad H, Ma C, Yano H, Pan C, Ohnishi K, Fujiwara Y, Endo S, Kikukawa Y, Okuno Y, Matsuoka M, Takeya M, Komohara Y (2016) An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma. Cancer Sci 107:1696–1704

Zeng Q, Li S, Zhou Y, Ou W, Cai X, Zhang L, Huang W, Huang L, Wang Q (2014) Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcinoma via NF-kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 65:24–32

Sorrentino C, Di Carlo E (2009) Expression of IL-32 in human lung cancer is related to the histotype and metastatic phenotype. Am J Respir Crit Care Med 180:769–779

Okimoto T, Kotani H, Iida Y, Koyanagi A, Tanino R, Tsubata Y, Isobe T, Harada M (2020) Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells. Cancer Sci 111:1910–1920

Hong JT, Son DJ, Lee CK, Yoon DY, Lee DH, Park MH (2017) Interleukin 32, inflammation and cancer. Pharmacol Ther 174:127–137

Park MH, Yoon DY, Ban JO, Kim DH, Lee DH, Song S, Kim Y, Han SB, Lee HP, Hong JT (2015) Decreased severity of collagen antibody and lipopolysaccharide-induced arthritis in human IL-32beta overexpressed transgenic mice. Oncotarget 6:38566–38577

Kang JW, Choi SC, Cho MC, Kim HJ, Kim JH, Lim JS, Kim SH, Han JY, Yoon DY (2009) A proinflammatory cytokine interleukin-32beta promotes the production of an anti-inflammatory cytokine interleukin-10. Immunology 128:e532–e540

Hough JT, Zhao L, Lequio M, Heslin AJ, Xiao H, Lewis CC, Zhang J, Bai Q, Wakefield MR, Fang Y (2023) IL-32 and its paradoxical role in neoplasia. Crit Rev Oncol Hematol 186:104011

Antonangeli F, Natalini A, Garassino MC, Sica A, Santoni A, Di Rosa F (2020) Regulation of PD-L1 expression by NF-kappaB in cancer. Front Immunol 11:584626

Lei J, Xu F, Deng C, Nie X, Zhong L, Wu Z, Li J, Wu X, He S, Chen Y (2023) Fusobacterium nucleatum promotes the early occurrence of esophageal cancer through upregulation of IL-32/PRTN3 expression. Cancer Sci 114:2414–2428

Sun Y, Qian Y, Chen C, Wang H, Zhou X, Zhai W, Qiu L, Zhou X, Ning H, Zhao Y, Shi C, Han L, Qi Y, Wu Y, Gao Y (2022) Extracellular vesicle IL-32 promotes the M2 macrophage polarization and metastasis of esophageal squamous cell carcinoma via FAK/STAT3 pathway. J Exp Clin Cancer Res 41:145